Miniaturized Platforms & Methods for Pharmaceutical Studies
Current pharmaceutical studies are often limited by high cost due to consumption of large amounts of precious reagents and reliance on bulky and expensive instrumentations. To address these challenges, significant advances have been achieved during the past few decades to miniaturize current pharmaceutical study platforms to decrease the cost, and to enhance the portability and throughput.
These miniaturized platforms include but not limited to microfluidic lab-on-a-chip platforms, nanofluidic platforms, nanosensors, capillary electrophoresis and so on. For instance, numerous microfluidic lab-on-a-chip platforms that debuted since the 1990s, have been developed and used in different pharmaceutical applications, which include drug discovery, drug separation and analysis, drug delivery and so on. Therefore, I as a guest editor organized this special issue of "Miniaturized platforms and methods for pharmaceutical studies", and invited worldwide experts in this field to highlight recent advances of different miniaturized platforms and methods for pharmaceutical studies, with an emphasis on microfluidic lab-on-a-chip platforms. These platforms and methods target to a broad range of pharmaceutical applications, such as drug metabolism and cytotoxicity study, drug testing and analysis, drug delivery, circulating tumor cell isolation, point-of-care study, and so on. Experts also comment on current limitations and future perspectives of different specific techniques.
Metabolism and cytotoxicity studies of drug candidates are essential steps during drug development. Mattgew Lockett et al. present a comprehensive review regarding microfabricated devices for studying the metabolism and cytotoxicity of drug candidates. Microfabricated devices integrate multiple reaction steps in a single device and decrease the cost of a single metabolism or cytotoxicity screen. The incorporation of three-dimensional co-cultures in these devices increases accuracy of in vitro screens. They highlight technologies that have the potential of reaching shorter-and longer-term goals of reducing the cost of bringing new drugs to market and revolutionizing the discovery stage of the drug development pipeline.
XiuJun Li et al. summarize state of the art of microfluidic/nanofluidic technologies for controlled drug delivery, including microreservoir-based delivery systems and microneedles. Therapeutic drugs administered systematically are evenly distributed to the whole body through blood circulation. Conventional drug delivery may make drugs inactive or reduce their potency as they may be hydrolyzed or degraded enzymatically and are rapidly excreted through the urinary system resulting in suboptimal concentration of drugs at the desired site. Controlled drug delivery aims to localize the pharmacological activity of the drug to the desired site at desired release rates. The advances made by micro/nanofluidic technologies have provided new opportunities for better-controlled drug delivery. show that the slurry complexation method is the best among a few methods used in preparation of the complex. Pharmacological results also confirm that the complex promotes antihypertensive effect.
